Twenty Questions for Phosphagenics

Apologies in advance for what is a fairly long post… In the usual stream of announcements and news feeds yesterday, I read the ASX release from Phosphagenics (ASX : POH) regarding their Oxycodone PHN study. Now I don’t comment much on this company, despite the fact that they are fairly visible in the public domain. About…

Phylogica : 600% Effective

Always good to get a pearl out of Phylogica (ASX : PYC) informing us that their latest “petri dish” experiment works 600% better than a previous “petri dish” experiment. Also nice to see approximately 600% abuse of ASX continuous disclosure rules… Instead of writing yet another rant about PYC’s rubbish in vitro studies, I am going to…

The Company that Advised Itself

Last night as my plane leveled off at 30,000 ft I decided to get stuck into a glass of wine and the Biotech Daily. While flicking through the bioscience news de jour, I saw the following comment about IQ3 Group (ASX : IQ3): IQ3 says it has been appointed as corporate advisor to the Iqnovate agreement to…

Starpharma Sensationalism – MkII

As a number of (slightly cocky and goading) readers pointed out today, my prior post on Starpharma’s utterly stupid pre-clinical announcement had a major flaw. In the interest of being comprehensive, I would like to make an additional follow-up comment, while simultaneously acknowledging my own incompetence and stupidity. I was too busy telling you about…

Starpharma Sensationalism

Really? REALLY? Yesterday Starpharma (ASX : SPL) announced that it had done some mouse models with a Herceptin-conjugated DEP dendrimer. It wasn’t peer reviewed data. It wasn’t an exhaustive pre-clinical package. It was just a one-off science experiment packaged up and served to retail investors as company propaganda. 20 mice. The company even states that…

Because an Emu Wouldn’t Fit in the Oven…

One of my great hopes for the Australian biosciences scene is that we get to a stage of market information quality that retail investors can read and use a critical assessment of a biotech stock, and actually take note rather than just get their knickers in a twist. It requires many ecosystem changes but if we want to…